* signs and symptoms consistent with covid-19 upon screening * history of covid-19 * presence of uncontrolled cardiovascular, hematologic, respiratory, hepatic, renal, gastrointestinal, or neuropsychiatric disease * presence of diabetes mellitus * presence of active autoimmune disease * positive for hbc, hcv or hiv antibody * history of anaphylactic shock * history of epilepsy * presence of active malignancy * presence of lung disease (e.g., copd, asthma) * positive urine pregnancy test within 24 hours * pregnant, lactating, planned pregnancy of self (if female) or partner (if male) within 90 days after administration of the trial drug * if female and premenopausal, not agreeable to contraception for 90 days after second administration of the trial drug * if male, not agreeable to contraception for 90 days after second administration of the trial drug * presence of clinically relevant electrocardiogram or vital sign abnormality at screening * participated in a clinical trial of a drug or a medical device within 30 days or a biologic within 90 days * received any sars-cov-2 vaccine * received within 90 days, or is planning to receive during the study period, an immunoglobulin or blood product * received within 180 days, or is planning to receive during the study period, a biologic product with immunosuppressive properties * received for 14 days or more within 180 days, or is planning to receive during the study period, a corticosteroid * deemed ineligible for the study as determined by the principal investigator or a co-investigator

* signs and symptoms consistent with covid-19 upon screening * history of covid-19 * presence of uncontrolled cardiovascular, hematologic, respiratory, hepatic, renal, gastrointestinal, or neuropsychiatric disease * presence of diabetes mellitus * presence of active autoimmune disease * positive for hbc, hcv or hiv antibody * history of anaphylactic shock * history of epilepsy * presence of active malignancy * presence of lung disease (e.g., copd, asthma) * positive urine pregnancy test within 24 hours * pregnant, lactating, planned pregnancy of self (if female) or partner (if male) within 90 days after administration of the trial drug * if female and premenopausal, not agreeable to contraception for 90 days after second administration of the trial drug * if male, not agreeable to contraception for 90 days after second administration of the trial drug * presence of clinically relevant electrocardiogram or vital sign abnormality at screening * participated in a clinical trial of a drug or a medical device within 30 days or a biologic within 90 days * received any sars-cov-2 vaccine * received within 90 days, or is planning to receive during the study period, an immunoglobulin or blood product * received within 180 days, or is planning to receive during the study period, a biologic product with immunosuppressive properties * received for 14 days or more within 180 days, or is planning to receive during the study period, a corticosteroid * deemed ineligible for the study as determined by the principal investigator or a co-investigator

- signs and symptoms consistent with covid-19 upon screening - history of covid-19 - presence of uncontrolled cardiovascular, hematologic, respiratory, hepatic, renal, gastrointestinal, or neuropsychiatric disease - presence of diabetes mellitus - presence of active autoimmune disease - positive for hbc, hcv or hiv antibody - history of anaphylactic shock - history of epilepsy - presence of active malignancy - presence of lung disease (e.g., copd, asthma) - positive urine pregnancy test within 24 hours - pregnant, lactating, planned pregnancy of self (if female) or partner (if male) within 90 days after administration of the trial drug - if female and premenopausal, not agreeable to contraception for 90 days after second administration of the trial drug - if male, not agreeable to contraception for 90 days after second administration of the trial drug - presence of clinically relevant electrocardiogram or vital sign abnormality at screening - participated in a clinical trial of a drug or a medical device within 30 days or a biologic within 90 days - received any sars-cov-2 vaccine - received within 90 days, or is planning to receive during the study period, an immunoglobulin or blood product - received within 180 days, or is planning to receive during the study period, a biologic product with immunosuppressive properties - received for 14 days or more within 180 days, or is planning to receive during the study period, a corticosteroid - deemed ineligible for the study as determined by the principal investigator or a co-investigator

- signs and symptoms consistent with covid-19 upon screening - history of covid-19 - presence of uncontrolled cardiovascular, hematologic, respiratory, hepatic, renal, gastrointestinal, or neuropsychiatric disease - presence of diabetes mellitus - presence of active autoimmune disease - positive for hbc, hcv or hiv antibody - history of anaphylactic shock - history of epilepsy - presence of active malignancy - presence of lung disease (e.g., copd, asthma) - positive urine pregnancy test within 24 hours - pregnant, lactating, planned pregnancy of self (if female) or partner (if male) within 90 days after administration of the trial drug - if female and premenopausal, not agreeable to contraception for 90 days after second administration of the trial drug - if male, not agreeable to contraception for 90 days after second administration of the trial drug - presence of clinically relevant electrocardiogram or vital sign abnormality at screening - participated in a clinical trial of a drug or a medical device within 30 days or a biologic within 90 days - received any sars-cov-2 vaccine - received within 90 days, or is planning to receive during the study period, an immunoglobulin or blood product - received within 180 days, or is planning to receive during the study period, a biologic product with immunosuppressive properties - received for 14 days or more within 180 days, or is planning to receive during the study period, a corticosteroid - deemed ineligible for the study as determined by the principal investigator or a co-investigator